Recent News

• 03.13.2026 - AC Immune Reports Full Year 2025 Financial Results and Provides a Corporate Update
• 10.28.2025 - AC Immune Appoints Renowned Neurologist Catherine Mummery as Chair of Clinical Advisory Board
• 10.24.2025 - First Characterization of a TDP-43 PET Tracer Published in Nature Communications Showing Potential of AC Immune’s ACI-19626 in Precision Medicine
• 09.25.2025 - Peer-reviewed results from Phase 1b/2a Trial of Anti-pTau Active Immunotherapy from AC Immune Published in eBioMedicine
• 09.25.2025 - Peer-reviewed results from Phase 1b/2a Trial of Anti-pTau Active Immunotherapy from AC Immune Published in eBioMedicine
• 09.25.2025 - Peer-reviewed results from Phase 1b/2a Trial of Anti-pTau Active Immunotherapy from AC Immune Published in eBioMedicine
• 09.04.2025 - AC Immune Sharpens Pipeline Focus with Operational Efficiencies Extending Cash Runway
• 09.04.2025 - AC Immune Sharpens Pipeline Focus with Operational Efficiencies Extending Cash Runway
• 09.04.2025 - AC Immune Sharpens Pipeline Focus with Operational Efficiencies Extending Cash Runway

Recent Filings

• 02.24.2026 - EX-99.1 EX-99.1
• 02.24.2026 - 6-K Report of foreign issuer [Rules 13a-16 and 15d-16]
• 02.17.2026 - 6-K Report of foreign issuer [Rules 13a-16 and 15d-16]
• 01.15.2026 - 144 Report of proposed sale of securities
• 12.11.2025 - 6-K Report of foreign issuer [Rules 13a-16 and 15d-16]
• 12.11.2025 - EX-99.1 EX-99.1
• 11.04.2025 - 6-K Report of foreign issuer [Rules 13a-16 and 15d-16]
• 11.04.2025 - EX-99.1 EX-99.1
• 10.03.2025 - 144 Report of proposed sale of securities
• 09.12.2025 - 144 Report of proposed sale of securities